Table 4 Respondent willingness to participate in clinical trials (N = 1,515)

Gender

Male

204/753 (27.1)

3.665

.056^a

Female

174/762 (22.8)

Age (years)

19~29

64/295 (21.7)

1.205

.272^b

30’s

89/375 (23.7)

40’s

114/411 (27.7)

50’s

68/250 (27.2)

≥60

43/184 (23.4)

Education

≤ High school

240/958 (25.1)

0.014

.905^a

≥ College

138/557 (24.8)

Resident areas

Large city

190/720 (26.4)

3.161

.075^b

Small city

155/623 (24.9)

Rural area

33/172 (19.2)

Household income

<2,000

89/347 (25.6)

0.213

.644^b

(1,000 won/month)

2,000 ∼ 2,999

109/406 (26.8)

3,000 ∼ 3,999

79/353 (22.4)

≥4,000

97/390 (24.9)

Living style

Alone

26/76 (32.9)

2.834

.092^a

With family

351/1433 (24.5)

Perception on ultimate beneficiary of CT

Pharmaceutical company

85/463 (18.4)

18.473

<.001^a

Hospital or physician

30/136 (22.1)

Patients

195/678 (28.8)

Advances in medicine

68/236 (28.8)

Experience of CT participation

No

302/1114 (27.1)

4.131

.042^a

Yes

11/24 (45.8)

Awareness of CT

No

65/377 (17.2)

15.929

<.001^a

Yes

313/1138 (27.5)

Favorable feeling toward CT

Low

25/327 (7.6)

157.311

<.001^b

Moderate

128/680 (18.8)

High

225/508 (44.3)

Safety toward CT

Low

28/410 (6.8)

240.003

<.001^b

Moderate

189/848 (22.3)

High

161/257 (62.6)

Necessity toward CT

Low

2/87 (2.3)

63.434

<.001^b

Moderate

52/366 (14.2)

High

324/1062 (30.5)